REPCF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 Mar 2024 @ 11:20):

Stats
Today's Volume	550.00
Average Volume	626.00
Market Cap	2.38M
EPS	$0 ( 2024-05-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.28
ATR14	$0 (0.00%)

RepliCel Life Sciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

RepliCel Life Sciences Financials

Annual	2023
Revenue:	$353 735
Gross Profit:	$352 264 (99.58 %)
EPS:	$-0.00530

FY	2023
Revenue:	$353 735
Gross Profit:	$352 264 (99.58 %)
EPS:	$-0.00530

FY	2022
Revenue:	$353 735
Gross Profit:	$353 735 (100.00 %)
EPS:	$-0.0341

FY	2021
Revenue:	$353 735
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.151

Financial Reports:

No articles found.

RepliCel Life Sciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

RepliCel Life Sciences

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.